Recent Quotes (30 days)

You have no recent quotes
chg | %

Aralez Pharmaceuticals Inc  

(Public, NASDAQ:ARLZ)   Watch this stock  
Find more results for ARLZ
1.62
0.00 (-0.31%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.57 - 1.68
52 week 0.95 - 4.65
Open 1.60
Vol / Avg. 436,804.00/576,320.00
Mkt cap 108.02M
P/E     -
Div/yield     -
EPS -1.68
Shares 1.00
Beta 1.44
Inst. own     -
May 3, 2018
Aralez Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Mar 12, 2018
Q4 2017 Aralez Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 13, 2018
Aralez Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Address

7100 West Credit Ave Suite 101
MISSISSAUGA, ON L5N 0E4
Canada
+1-905-8761118 (Phone)
+1-905-5674618 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Officers and directors

Arthur S. Kirsch Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Andrew Ian Koven President, Chief Business Officer
Age: 58
Bio & Compensation  - Reuters
Adrian Adams Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Michael Kaseta Head of Finance and Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Age: 42
Bio & Compensation  - Reuters
Jennifer Lou Armstrong Executive Vice President - Human Resources and Administration
Age: 45
Bio & Compensation  - Reuters
Eric L. Trachtenberg Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
Mark A. Glickman Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
James Patrick Tursi M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Kenneth B. Lee Jr. Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Neal Franklin Fowler Independent Director
Age: 54
Bio & Compensation  - Reuters